Clinical

Articles

Cemiplimab for patients with either metastatic or locally advanced basal cell carcinoma showed antitumor activity in a phase 2 trial.

Cemiplimab Shows Clinical Benefit for BCC After Hedgehog Inhibitor Therapy

Pembrolizumab has been granted an expanded indication by the FDA for locally advanced cutaneous squamous cell carcinoma.

FDA Expands Indication for Pembrolizumab in Locally Advanced CSCC

These data establish pembrolizumab as a promising treatment option for those with locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma, according to Brett G.M. Hughes, MD.

Pembrolizumab Induces Robust, Durable Antitumor Activity in Advanced CSCC

First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma

The PD-1 inhibitor cemiplimab was granted approval in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom these therapies are not appropriate. 

FDA Approves Cemiplimab as First Immunotherapy to Treat Patients With Advanced BCC

A study published in JAMA Dermatology found changes in diagnostics and awareness may, in part, account for initial increases in incidence rates for Merkel cell carcinoma.

Looking at MCC Diagnoses Over Time Reveal Varying Effects Account for Incidence Rates

Study investigators indicated that these results call for the need to revise skin cancer health policies to be able to handle the increasing burden of keratinocyte carcinoma management.

Study Finds Incidence Rates of cSCC Continue to Increase, Especially Among Females

A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.

Topical Immunosuppressants Drugs Don’t Increase Risk of Common Skin Cancers, Despite Warning Labels

Cemiplimab demonstrated an objective response rate of 31% in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors.

PD-1 antibody Induces Clinical Activity in Patients with Locally Advanced Basal Cell Carcinoma

Data released from a phase 2b clinical trial showed statistically significant long-term survival for patients with stage III or IV melanoma at high-risk of recurrence.

Skin Cancer | Topics